AdvanCell is developing therapies to treat cancers including: prostate, skin, pancreatic, breast, bladder, colorectal, kidney ...
Citi raised the firm’s price target on Exelixis (EXEL) to $45 from $38 and keeps a Buy rating on the shares following the Q4 report. The ...
News Medical on MSN4h
Globally prostate and testicular cancer rates climb, but mortality is fallingNew research maps the global burden of male cancers from 1990 to 2040, showing how aging, lifestyle, and healthcare access ...
Medical review of Phase 1 cohorts demonstrated no safety issuesData to be presented at the 10th Annual Innate Killer Summit, March 3-5BOCA RATON, ...
A groundbreaking study has uncovered how specific genetic mutations influence cancer treatment outcomes -- insights that could help doctors tailor treatments more effectively. The largest study of its ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.BoQAct6R.js ...
More than 67,000 Americans will be diagnosed with pancreatic cancer this year. Learn more about the disease and how PanCAN can help.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback